Table 3.
Body mass index variation in adult Turner Syndrome patients stratified by the types of progestin used in the hormone replacement therapy.
| Progestin | N | Ageyo. | Timeyr. | SPCD | Initial BMIKg/m2 | After BMIKg/m2 |
|---|---|---|---|---|---|---|
| MPA | 12 | 22.6 ± 3.6* | 5.5 ± 2.0* | 6.0*(1.0 to 11.9) | 22.9 ± 4.1* | 25.5 ± 5.9 |
| LGN | 14 | 25.0 ± 6.1 | 3.4 ± 1.9 | 2,8(1.3 to 7.5) | 24.5 ± 4.4** | 24.9 ± 4.3 |
| MP | 11 | 29.3 ± 5.4 | 1.8 ± 0.7 | 1,6(1.1 to 4.3) | 28.7 ± 4.0 | 29.7 ± 4.2 |
| Total | 37 | 25.5 ± 5.8 | 3.6 ± 2.5 | 2.6(1.0 to 11.9) | 25.3 ± 4.7 | 26.5 ± 5.2 |
Data expressed as mean ± SD for parametric and as median – minimum/maximum for nonparametric data distribution by different types of progestins during the long-retrospective assessment. This subgroup comprises 37/73 TS adult patients enrolled in Phase 2.3.
MPA medroxyprogesterone, LNG levonorgestrel. MP micronized progesterone; SPCD standard progestin cumulative dose; BMI body mass index. Differences in mean values among the groups are greater than would be expected by chance (p < 0,05); *MPA vs MP, **LNG vs MP.